Zynerba Pharmaceuticals Inc updates on its meeting with the US Food and Drug Administration regarding its Fragile X syndrome program using Zygel
Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About
SCYNEXIS Inc names Zynerba Pharmaceuticals Inc CEO Armando Anido to its board
g260361mmi021.gif
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients (NASDAQ:ZYNE) | Seeking Alpha
Zynerba: Transdermal Cannabinoids Have Significant Potential (NASDAQ:ZYNE) | Seeking Alpha
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/YST6UFBNEVBAXNOUKDYSHHF4AM.PNG "Synthetic CBD from Main Line biotech gets fast track status from FDA")
Synthetic CBD from Main Line biotech gets fast track status from FDA
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharmaceuticals receives FDA approval for cannabinoid therapies
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products
Zynerba sinks after total failure in phase 2 cannabidiol trial | Fierce Biotech
Zynerba hopes to crack fragile X at last | Evaluate
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
Zynerba Synthetic CBD Gel for Epilepsy Proves Safe but Not Effective in FDA Phase 2 Trial – New Cannabis Ventures
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Zygel - Zynerba
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
zynerba-pipeline-10-16 - Zynerba
